Morgan Stanley’s Pasithea Therapeutics KTTA Stock Holding History

Morgan Stanley’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000	Closed	-$3.15K	–	8164
2024 Q4	$3.15K	Sell	1,000 -500	-33%	-$1.77K	﹤0.01%	7106
2024 Q3	$8.13K	Buy	+1,500	New	+$7.39K	﹤0.01%	6777

Other funds holding KTTA

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hurley Capital New York $187M AUM 23.24% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley's KTTA Position: Q1 2025 in Review

Morgan Stanley sold out of Pasithea Therapeutics (KTTA) in Q1 2025, closing a stake of 1,000 shares — an estimated $3.15K sold.

Morgan Stanley first reported a position in KTTA in Q3 2024 and held it in 2 quarters. The position peaked at $8.13K in Q3 2024. 8 funds tracked by Wall St. Rank hold KTTA as of Q1 2025.

Morgan Stanley reported no remaining Pasithea Therapeutics position as of Q1 2025 after selling out during the quarter.
Morgan Stanley sold 1,000 Pasithea Therapeutics shares in Q1 2025, an estimated $3.15K.
Morgan Stanley first reported a position in Pasithea Therapeutics in Q3 2024 and held it in 2 quarters.
Morgan Stanley's Pasithea Therapeutics position peaked at $8.13K in Q3 2024.
8 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.